Strategies for Setting Patient-Centric Commercial Specifications for Biotherapeutic Products.

Journal of pharmaceutical sciences 2021 Feb

filter terms:

Commercial specifications for a new biotherapeutic product are a critical component of the product's overall control strategy that ensures safety and efficacy. This paper describes strategies for setting commercial specifications as proposed by a consortium of industry development scientists. The specifications for some attributes are guided by compendia and regulatory guidance. For other product quality attributes (PQAs), product knowledge and the understanding of attribute criticality built throughout product development should drive specification setting. The foundation of PQA knowledge is an understanding of potential patient impact through an assessment of potency, PK, immunogenicity and safety. In addition to PQA knowledge, the ability of the manufacturing process to consistently meet specifications, typically assessed through statistical analyses, is an important consideration in the specification-setting process. Setting acceptance criteria that are unnecessarily narrow can impact the ability to supply product or prohibit consideration of future convenient dosage forms. Patient-centric specifications enable appropriate control over higher risk PQAs to ensure product quality for the patient, and flexibility for lower risk PQAs for a sustainable supply chain. This paper captures common strategic approaches for setting specifications for standard biotherapeutic products such as monoclonal antibodies and includes considerations for ensuring specifications are patient centric. Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Citation

Margaret N Ruesch, Luca Benetti, Eileen Berkay, David J Cirelli, Neha Frantz, Martin H Gastens, Wayne P Kelley, Juliana Kretsinger, Mike Lewis, Shawn Novick, Barbara Rellahan, Laura Pack, Corné J M Stroop, Ann Subashi, Ping Yin, Ming Zeng, John Stults. Strategies for Setting Patient-Centric Commercial Specifications for Biotherapeutic Products. Journal of pharmaceutical sciences. 2021 Feb;110(2):771-784